Dr. Reddy's Laboratories acquires Preferred A-1 shares of Edity Therapeutics

The acquisition is done through cash consideration, by way of conversion of SAFE (Simple Agreement for Future Equity) investment of US$ 2 Million to Preferred A-1 Shares

Briefs: Dr. Reddy's Laboratories and Aurobindo Pharma

The inspection closed with zero observations and a classification of No Action Indicated

Dr. Reddy's Laboratories Q1 FY2024 consolidated PAT jumps to Rs. 1402.5 Cr

The company has reported total income of Rs. 6738.4 crores during the period ended June 30, 2023

Briefs: Shivalik Rasayan and Dr. Reddy's Laboratories

Shivalik Rasayan Limited has issued LOA to Medicamen Biotech to use its DMF grade Bortezomib API for formulation of Bortezomib injection 3.5mg/ vial

Dr Reddys Laboratories signs for consumption of renewable energy

Mandaviya focuses on high value pharmaceuticals and high-end medical devices to reduce the import dependency

First release of Rs.166 crores incentives under PLI scheme for pharmaceuticals

Dr. Reddys Laboratories Q3 FY2023 consolidated PAT up to Rs. 1243.9 Cr

The company has reported total income of Rs. 6848.5 crores during the period ended December 31, 2022

Claim against Dr. Reddy’s Laboratories dismissed over Revlimid in US

All claims against the company in the litigation have now been dismissed.

Dr. Reddy's Laboratories announces conclusion of patent litigation with Indivior

The settlement and dismissal resolves all claims between the parties

Dr. Reddy's announces commercial launch of 2DG

2-DG was developed by the Institute of Nuclear Medicine & Allied Sciences (INMAS), a laboratory of the Defence Research and Development Organisation (DRDO), in collaboration with Dr. Reddy's